Cell Signaling Technology

Product Pathways - Tyrosine Kinase / Adaptors

FLT3 (8F2) Rabbit mAb #3462

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP IHC-P H M Endogenous 130 nonglycosylated form;160 glycosylated mature form Rabbit IgG

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IHC-P=Immunohistochemistry (Paraffin)
Reactivity Key:  H=Human  M=Mouse
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

FLT3 (8F2) Rabbit mAb detects endogenous levels of FLT3 protein. The antibody does not cross-react with related proteins.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to the sequence surrounding Ser740 of human FLT3.

Western Blotting

Western Blotting

Western blot analysis of extracts from Baf3/FLT3 transfected cells and SEM leukemia cells, using FLT3 (8F2) Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded SEM cells, using FLT3 (8F2) Rabbit mAb.

Background

FMS-related tyrosine kinase 3 (FLT3, also called Flk2), is a member of the type III receptor tyrosine kinase family, which includes c-Kit, PDGFR and M-CSF receptors. FLT3 is expressed on early hematopoietic progenitor cells and supports growth and differentiation within the hematopoietic system (1,2). FLT3 is activated after binding with its ligand FL, which results in a cascade of tyrosine autophosphorylation and tyrosine phosphorylation of downstream targets (3). The p85 subunit of PI3 kinase, SHP2, GRB2 and Shc are associated with FLT3 after FL stimulation (4-6). Tyr589/591 is located in the juxtamembrane region of FLT3 and may play an important role in regulation of FLT3 tyrosine kinase activity. Somatic mutations of FLT3 consisting of internal tandem duplications (ITDs) occur in 20% of patients with acute myeloid leukemia (7).

  1. Shurin, M.R. et al. (1998) Cytokine Growth Factor Rev. 9, 37-48.
  2. Naoe, T. et al. (2001) Cancer Chemother. Pharmacol. 48 Suppl1, S27-S30.
  3. Namikawa, R. et al. (1996) Stem Cells 14, 388-395.
  4. Beslu, N. et al. (1996) J. Biol. Chem. 271, 20075-20081.
  5. Zhang, S. and Broxmeyer, H.E. (2000) Biochem. Biophys. Res. Commun. 277, 195-199.
  6. Zhang, S. et al. (1999) J. Leukoc. Biol. 65, 372-380.
  7. Mizuki, M. et al. (2000) Blood 96, 3907-3914.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Rabbit Monoclonals Produced Using Epitomics® Technology, U.S. Patent No. 5,675,063.

For Research Use Only. Not For Use In Diagnostic Procedures.

Products